E-mail a Colleague

Site Map

U.S. Residents Only

Important Safety Info.

Prescribing Info.

Ordering & Reimbursement

Patient Web Site

About Osteoarthritis of the Knee

HYALGAN® Facts

When to Use HYALGAN®

How to Use HYALGAN®

HYALGAN® - Proven Efficacy

Clinical Trial Library

HCP Resources

Patient Support

It looks like you do not have an updated Flash Plug-in. To view the current page, please download it.

Keep HYALGAN® on hand.

Learn techniques to administer HYALGAN®.

Learn how HYALGAN® benefits your patients.

Register for HYALGAN® updates and special offers.

HYALGAN® Clinical Trial Library

HYALGAN® clinical trials

This section provides you with additional recently published articles about scientific studies, information about ongoing research and alternative treatments, clinical data, and informational materials regarding osteoarthritis.

Clinical Data

Altman RD, Moskowitz R, and the HYALGAN® Study Group. Intra-articular sodium hyaluronate (HYALGAN®) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol. 1998;25:2203-2212.

See abstract on the PubMed Web site >>

Carrabba M, Paresce E, Angelini M, Re KA, Torchiana EEM, Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm. 1995;15:25-31.

See abstract >>

Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology. 1999;38:602-607.

See abstract on the PubMed Web site >>

Scali JJ. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long term study. Eur J Rheumatol Inflamm. 1995;15:57-62.

See abstract >>

Important Safety Information for HYALGAN®

HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
The effectiveness of a single treatment cycle of less than 3 injections has not been established
In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

Click here for additional important information for HYALGAN®.